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Neuroinﬂammation in Parkinson’s disease (PD) is a chronic process that is associated with alteration of glial cells, including
astrocytes and microglia. However, the precise mechanisms remain obscure. To better understand neuroinﬂammation in PD,
we focused on glial activation in α-synuclein (αS) transgenic and related model mice. In the majority of αS transgenic mice,
astrogliosis was observed concomitantly with accumulation of αS during the early stage of neurodegeneration. However, microglia
were not extensively activated unless the mice were treated with lipopolysaccharides or through further genetic modiﬁcation of
other molecules, including familial PD risk factors. Thus, the results in αS transgenic mice and related model mice are consistent
with the idea that neuroinﬂammation in PD is a double-edged sword that is protective in the early stage of neurodegeneration but
becomes detrimental with disease progression.
1.Introduction
The neurodegenerative brain in Parkinson’s disease (PD) is
characterized by protein aggregation of α-synuclein (αS),
formation of Lewy bodies and Lewy neuritis, extensive
loss of dopaminergic neurons, and gliosis in the substantia
nigra [1, 2]. Similar αS pathologies have been observed in
various types of α-synucleinopathies, including Dementia
with Lewy Bodies (DLB), multiple system atrophy (MSA),
neurodegeneration with brain iron accumulation, type 1,
and the Lewy body variant of Alzheimer’s disease (AD)
[2]. Mechanistically, a wealth of data has suggested that
neurotoxicity is well correlated with formation of oligomers
and protoﬁbrils of αS[ 3]. Immature ﬁbrils of αSm a y
be causative for diverse neurodegenerative alterations such
as mitochondrial damage, increased endoplasmic reticulum
stress, loss of membrane integrity, dysfunction of the
ubiquitin-proteasome system, lysosomal leakage, and Golgi
fragmentation [4]. In contrast, mature ﬁbrils formed in the
late stage of aggregation of αS might be protective since they
may capture toxic and metastatic immature forms of αS,
sequestering them into Lewy bodies [3].
In addition to cell-autonomous neurotoxicity due to
aggregation of αS, mounting evidence from histology and
cell biology has suggested that non-cell-autonomous neu-
roinﬂammation may be crucial for neurotoxicity since aber-
rant activation of glial cells may stimulate inﬂammation,
leading to neuronal cell death [5, 6]. This view has been
supported by recent progress in genetic studies. In particular,
a genomewide association studies (GWAS) demonstrated
association of a single nucleotide polymorphism (SNP) of
leucine-rich repeat kinase 2 (LRRK2) (park8) with both
sporadic PD [7, 8] and other inﬂammation-related disorders
such as Crohn’s disease [9]a n dl e p r o s y[ 10], establishing a
new concept that neuroinﬂammation may play a primary
role in neurodegeneration in PD.2 Parkinson’s Disease
Despite the central role of neuroinﬂammation in the
pathogenesis of PD and related α-synucleinopathies, the
precise mechanism is still unclear. Indeed, many concepts of
neuroinﬂammationhavebeenbasedontheresultsofParkin-
sonian models induced by treatment with agents such as 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-
hydroxydopamine, in which microglia are activated within
several hours after treatment and supply multiple neu-
rotoxic factors, including tumor necrosis factor-α, nitric
oxide, interleukin-1β, and reactive oxygen species, that drive
progressive neurodegeneration [11]. However, the extent to
whichresultsobtainedfromsuchacutemodelsareapplicable
to neuroinﬂammation in PD brains is yet to be determined,
since neuroinﬂammation is a chronic phenomenon that
occurs over decades and has a time course associated
with alteration of diﬀerent types of glial cells. Thus, the
main objective of this paper is to explore the mechanism
of neuroinﬂammation based on information derived from
transgenic (tg) mouse models of α-synucleinopathies.
2. Role of Astroglia in
Neuroinﬂammation in α-Synucleinopathies
Since the discovery of missense mutations of αS in familial
cases of PD, many tg mouse models of α-synucleinopathies
expressing full-length human wild-type or disease-linked
mutant αS have been created using neuron-speciﬁc pro-
moters such as platelet-derived growth factor-β [12], Thy-
1[ 13, 14], and prion protein [15, 16]. These αSt gm o d e l
mice recapitulate similar αS pathologies to those of PD
brains, such as formation of αS-positive accumulations in
neuronal cell bodies and neurites, a reduction of the density
of tyrosine hydrolase-positive terminals in the striatum,
and αS aggregation in detergent-insoluble fractions based
on biochemical analyses, although behavioral disorders
including deterioration of rotarod performance might be
due to degeneration of cortical neurons associated with αS
accumulation.
Reactive astrocytes are ubiquitously observed in various
neurodegenerative disorders. Consistent with this, astrocytic
gliosis has been shown in all αS tg mice. However, the
mechanisms through which astrocytes are consistently acti-
vated in the brains of αSt gm i c ea r ee l u s i v e .O n ep o s s i b l e
mechanism is direct stimulation of astrocytes by αSd e r i v e d
from degenerating neurons. In support of this view, recent
data suggest that αS may be released from neurons via a
nonclassical secretory pathway [17] and may therefore exert
paracrine eﬀects in the extracellular environment, which
might be related to propagation of αS to adjacent cells,
including neurons and astrocytes [18, 19]. Indeed, a sen-
sitive enzyme-linked immunosorbent assay in combination
with in vivo microdialysis was used to demonstrate the
presence of relatively high concentrations of αSi nb r a i n
interstitial ﬂuids [20]. Furthermore, it was shown that αS-
containing inclusion bodies are present in astrocytes [21],
althoughitisstillpossiblethatastrocytesthemselvesproduce
αS.
Since astrocytes have a multitude of protective functions,
including regulation of the ionic milieu in the intercellular
space, uptake and/or breakdown of glutamate, and main-
tenance of the integrity of the blood-brain barrier [22], it
is likely that, as long as astrocytes are intact in the early
stage of neurodegeneration, they may be protective against
neurodegeneration.Astrocytesmayperceivethedegenerative
conditions of neurons through detection of neuron-de-
rived αS and are subsequently activated to protect neurons.
However, such reactive astrocytes are exposed to increasing
toxicity of αS oligomers and/or protoﬁbrils, until they
are no longer protective (loss of function). Alternatively,
astrocytes might become aberrantly activated during the
long time course of neurodegeneration (gain of function).
It is also possible that the presence of such aberrantly
reactive astrocytes could be a prerequisite for activation of
microglia. Whichever the case, astrocytes may be regarded
as critical regulators of neuroinﬂammation. Notably, this
notion is supported by recent work by Gu and colleagues,
who created tg mice with astrocytic overexpression of A53T
mutant αS under regulation by the tetracycline operator
[23]. These mice exhibited extensive phenotypes, such as
rapid progressive paralysis, accumulation of αSa g g r e g a t e s ,
expansion of reactive astrogliosis, and microglial activa-
tion, whereas the normal function of astrocytes seemed
to be compromised, as evidenced by cerebral microhem-
orrhage and downregulation of astrocytic glutamate trans-
porters.
3. Role of EnvironmentalFactorsin
Neuroinﬂammation in α-Synucleinopathies
Compared to the extensive formation of reactive astrocytes,
activated microglia are rarely detected in αSt gm i c e .T h e
mechanism is still elusive, but it is possible that additional
factors might be required to enhance neuroinﬂammation
associated with microglia in these mice. Indeed, the loss of
nigral dopaminergic neurons in idiopathic PD is believed
to result from interactions between genetic susceptibility
and environmental factors [24]. Based on this idea, Gao
and colleagues injected an inﬂammagen, lipopolysaccharide
(LPS), into the substantia nigra of A53T mutant αSt g
mice and found that neuroinﬂammation was associated with
dopaminergic neuronal death and accumulation of insoluble
aggregated αS as cytoplasmic inclusions in nigral neurons
[25]. Furthermore, nitrated/oxidized αSw a sd e t e c t e di n
these inclusions and inhibition of microglia-derived nitric
oxide and superoxide resulted in neuroprotection in neuron-
glia cultures, suggesting that nitric oxide and superoxide
released by activated microglia may be mediators that link
inﬂammation and abnormal αS in mechanisms of PD
neurodegeneration. Essentially similar results were obtained
by intraperitoneal injection of LPS in αSt gm i c e[ 26]. These
results led the authors to propose a two-hit model in which
mutant αS and inﬂammation work in concert to mediate
chronic PD neurodegeneration [11]. Supporting the role ofParkinson’s Disease 3
viral infections in the pathogenesis of α-synucleinopathies, it
was shown that intranasal administration of the neurotropic
virus H5N1 resulted in αS aggregation and microglial
activation [27]. Since it is still unclear whether other types
of infections are related to the elevations of PD risks [11],
further epidemiologic studies are warranted to test this in-
triguing hypothesis.
4. Alteration of Familial PD Risk Factors
Leads to EnhancedNeuroinﬂammation
Besides αS (PARK1, PARK4), there is increasing evidence to
suggest that familial PD risk factors may be involved in both
cell-autonomous and non-cell-autonomous neurotoxicities.
Theresultsofknockoutmousestudiesofautosomalrecessive
factors such as parkin (PARK2), PINK1 (PARK6), and DJ-1
(PARK7) suggest that, in addition to cell-autonomous pro-
tective functions for neurons, these factors may be involved
in the negative regulation of neuroinﬂammation. Parkin,
mutations of which are present in at least 50% of patients
with autosomal recessive juvenile parkinsonism [29], is a
ubiquitin E3 ligase [30]. This ﬁnding led to establishment
of the importance of the ubiquitin/proteasome system in
α-synucleinopathies. Subsequently, PINK1, a mitochondri-
ally targeted Ser/Thr kinase of which mutations are the
second most frequent cause of autosomal recessive young-
onset PD [31], was shown to cooperate with parkin in
maintenance of mitochondrial quality, and mutations in
these genes were causative for mitophagy [32]. Although
Parkin (−/−) mice do not display nigrostriatal pathway
degeneration, these mice displayed subtle ﬁne-motor deﬁcits
and selective loss of DA neurons in the substantia nigra
when intraperitoneally treated with LPS [33]. Similarly, the
numbers of dopaminergic neurons and levels of striatal DA
and DA receptors were unchanged in PINK1(−/−)m i c e ;
however, these mice had increased levels of IL-1β, IL-12, and
IL-10 in the striatum after peripheral challenge with LPS,
and PINK1(−/−) embryonic ﬁbroblasts showed decreased
basal and inﬂammatory cytokine-induced nuclear factor
kappa-β activity [34]. Thus, Parkin and PINK1 deﬁciencies
collectively increase the vulnerability of nigral DA neurons
to inﬂammation-related degeneration.
Loss of function of DJ-1 has been linked to autosomal
recessive PD [35] and Parkinsonism-dementia-amyotrophic
lateral sclerosis complex [36]. Since DJ-1 is abundantly
expressed in reactive astrocytes [37], it was assumed that DJ-
1 might be involved in regulation of astrocytic activation
or some astrocytic functions. In this context, Waak and
colleagues showed that LPS treatment of astrocyte cul-
tures from DJ-1(−/−) mice displayed enhanced features of
inﬂammation, such as nitric oxide, inducible nitric oxide
synthase, cyclooxygenase-2, and IL-6, compared with LPS-
treated astrocytes from littermate controls [38].Theseresults
suggest that DJ-1 might act as a negative regulator of proin-
ﬂammatory responses in astrocytes and that loss of DJ-1
might contribute to PD pathogenesis through deregulation
of astrocytic neuroinﬂammatory damage [38].
Compared toautosomalrecessivefactors,itis morelikely
that the autosomal dominant factor, LRRK2, may play a
critical role in the pathogenesis of sporadic PD. Indeed,
mutations in LRRK2 are linked to the most common familial
autosomal dominant types of late-onset PD, as well as
some cases of sporadic PD [39, 40]. Notably, many LRRK2
mutation carriers exhibit typical PD symptoms that are clin-
ically indistinguishable from sporadic PD [40]. Consistent
with this, ﬁndings from GWAS recently demonstrated that
two autosomal dominant genes for familial PD, αSa n d
LRRK2, are strongly associated with sporadic PD [7, 8].
In this context, αS and LRRK2 appear to be commonly
involved in pathologies such as impairment of cytoskeleton
dynamics, dysregulation of the protein degradation system,
and enhanced protein aggregation. Thus, it was predicted
that, similarly to αS, LRRK2 might be involved in neu-
roinﬂammation in sporadic cases of PD and related α-
synucleinopathies.
The role of LRRK2 in neuroinﬂammation was demon-
strated by Lin and colleagues through generation of
LRRK2 knockout (−/−) and transgenic mice express-
ing human wildtype, G2019S mutant, or kinase-domain-
deletion LRRK2 under the transcriptional control of a tetra-
cycline operator [41]. Neither deletion nor overexpression of
LRRK2 caused overt gross neuropathological abnormalities
inmutantmice.However,cross-experimentsshowedthatthe
presence of excess LRRK2 greatly accelerated the progression
of neuropathological abnormalities developed in PD-related
A53T αS transgenic mice, such as abnormal aggregation
and somatic accumulation of αSi m p a i r m e n to fm i c r o -
tubule dynamics, Golgi organization, and the ubiquitin-
proteasome pathway. In these bigenic mice, the neurode-
generation was further characterized by neuronal cell death
associated with reactive astrocytes and activated microglia.
Conversely, inhibition of LRRK2 expression reduced the
aggregation/accumulation of αS and delayed progression
of αS-mediated neuropathology. These results suggest that
LRRK2 might be involved in the toxic gain of functions of
αS. In this regard, it is worth noting that LRRK2-knockout
mice showed PD-like pathology, such as αSa g g r e g a t i o n
and impairment of autophagy-lysosome pathway in their
kidneys [42]. Thus, the pathogenic mechanisms of LRRK2
are complicated and one possible interpretation may be the
dominant negative mechanism of LRRK2 for the potential
role of this molecule in protein degradation.
Curiously, GWAS ﬁndings have demonstrated that a
certain SNP in LRRK2 is associated with inﬂammatory
bowel diseases such as Crohn’s disease and ulcerative col-
itis [9]. Furthermore, SNPs of LRRK2 and parkin were
both associated with leprosy, a chronic infectious disease
caused by Mycobacterium leprae [10]. Thus, PD and α-
synucleinopathies are now genetically considered to be
within the spectrum of inﬂammatory diseases in which
LRRK2 and parkin might be involved. However, since the
SNPs of LRRK2 and Parkin that are positively linked to
inﬂammatory bowel diseases and leprosy diﬀer from those
linked to PD [7, 8], it is unclear whether the molecular
mechanisms are similar in α-synucleinopathies and other
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Figure 1: Characterization of glial activation in a P123HβSt gm o u s ea n da nαS/P123HβS bigenic mouse.(a) Concomitant with P123HβS-
positive dot-like axonal accumulation (upper),GFAP-positive reactive astrocytes were observed in the hippocampus of a P123HβSt gm o u s e ,
but not in a wild-type mouse (lower). Scale bar = 20μm. (b) Immunostaining with anti-CD11b antibody showed microglial activation in
an αS/P123HβS bigenic mouse, but not in a wild-type mouse. Scale bar = 20μm. The ﬁgures in (a) and (b) were reprinted from Fujita et al.,
[28], with permission, or are unpublished data related to the same paper.
5. Analysisof Neuroinﬂammation in
DLB-LinkedP123Hβ-Syn tgMice
Although previous studies have shown that βS plays a
neuroprotective role [43, 44], evidences are accumulating to
suggest that alteration of this molecule may also stimulate
neurodegeneration. In support of this notion, βSa n dγ-
synuclein (γS) are both associated with neuritic pathology,
such as in dystrophic neurites and spheroid structures, in the
brains of sporadic cases of PD, DLB [45], and neurodegen-
eration with brain iron accumulation, type I [46]. Thus, it
is probable that not only αS but also other synuclein family
members [47] might be involved in neuroinﬂammation.Two
missense mutations of βS have been discovered in unrelated
DLB [48]: a valine to methionine substitution at position 70
(V70M) was found in a sporadic DLB case in Japan, while
a proline to histidine mutation (P123H) was identiﬁed in
familial DLB cases in Seattle. Biochemical analysis in vitro
and cell culture studies suggested that nonamyloidogenic
βS was converted to aggregate-prone protein through gene
mutations, contributing to the pathogenesis of familial DLB
[49, 50].
To assess the consequences of excess expression of
P123HβS, we generated tg mice overexpressing P123HβS
under control of the Thy-1 promoter [28]. These mice were
characterized by memory dysfunction at a relatively early
age (∼6mo). Histopathological analyses revealed extensive
neuritic pathology that started at the same stage. P123HβS
accumulated in various brain regions, including apical den-
drites in the cortex and axonal deposits in the hippocampus
(Figure 1(a)). Notably, the same regions were accompa-
nied by massive gliosis, as revealed by an increased level
of glial ﬁbrillary-acidic-protein-(GFAP-) positive astroglia
(Figure 1(a)).IncontrasttoP123HβStgmice,neitherabnor-
mal immunostaining of P123HβS nor gliosis was observed
in non-tg littermates or in mice overexpressing wild-type βS
[28]. Extensive P123HβS-immunoreactive axonal swellings
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Figure 2: Schematic hypothesis of glial activations in the αS tg mouse. Astrocytes may quickly respond to αS released from degenerating
neurons to protect against neurodegeneration. During the long time course of neurodegeneration, these activated astrocytes may lose their
protective properties or might be aberrantly activated, leading to stimulation of neuroinﬂammation. This process may be stimulated by loss
of function of DJ-1. In contrast, microglia may be protective during the early stage of neurodegeneration and are not readily activated unless
they are stimulated with LPS or with alterations of other familial PD risk factors such as Parkin, PINK1, LRRK2, and other members of the
synuclein family of peptides, including mutant βS.
stage, but neither neuronal cell death nor microglia activa-
tion was observed.
Cross-breeding of a P123HβS tg mouse with an αSt g
mouse greatly enhanced neurodegeneration phenotypes,
which is reminiscent of the synergistic eﬀects between mu-
tant βSa n dαS in vitro [28]. In addition to aggregation of
P123HβSa n dαS, tyrosine hydroxylase was decreased and
motor dysfunctions were observed. Furthermore, microglia
were extensively activated (Figure 1(b)) concomitantly with
dark cell neurons, one type of neuronal cell death. These
results suggest that P123HβS may contribute to the αSp a -
thology in mouse brain.
Regarding γS, Ninkina and colleagues generated trans-
genic mice expressing high levels of mouse γS under control
of the Thy-1 promoter [51]. These mice developed severe age
and transgene dose-dependent neuropathology and motor
deﬁcits and died prematurely. Histopathological changes
included aggregation and accumulation of γSi nn e u r o n a l
cell bodies and processes, in addition to the presence of
γS-positive spheroids and dystrophic neuritis. Astrogliosis
was observed, but activation of microglia was not described,
suggesting that neuroinﬂammation was not extensive in
these mice
6. Role of Oligodendrocytes in
Neuroinﬂammation in α-Synucleinopathies
It is generally thought that oligodendrocytes are not involved
in neuroinﬂammation in PD. Nonetheless, the results ob-
tained from αS tg mice in a multiple system atrophy
(MSA) model may be important for understanding the role
of glial cells in neuroinﬂammation in α-synucleinopathies
[52–54]. Since MSA is histologically characterized by αS-
immunoreactive cytoplasmic inclusions in oligodendrocytes
[2], the pathogenic mechanism of MSA may be attributable
to alteration of oligodendrocytes by accumulation of αS. In
this context, tg MSA mouse models have been established
with expression of full-length wild-type or disease-linked
mutant αS under control of oligodendroglia-speciﬁc pro-
moters such as 2 ,3 -cyclic nucleotide 3 -phosphodiesterase
[52], myelin basic protein [53], and proteolipid protein
[54]. These αS tg mice develop extensive αS-immunoreactive
inclusions in oligodendrocytes in various brain regions,
including the neocortex, basal ganglia, cerebellum, and
brainstem, which are accompanied by myelin and neuronal
damage and motor deﬁcits, recapitulating features of MSA
[52–54].
There are at least two mechanisms through which altered
oligodendrocytes may stimulate neurodegeneration. First,
oligodendrocytes are speciﬁcally involved in myelination
[55], and their alterations may dysregulate myelination and
ultimately lead to axonal degeneration and synaptic loss.
Alternatively, since oligodendrocytes are the predominant
cells for glutamate clearance in human white matter [56],
alteration of oligodendrocytes might underlie accumulation
ofhighextracellularglutamateandproduceanincreasedrisk
for glutamate excitotoxicity.
A s t r o g l i o s i sw a so b s e r v e di na l lr e p o r t e dM S Am i c e ,
but no microglial activation was described [52–54]. In this
regard,itisworthnotingthatmicrogliamayplayaprotective6 Parkinson’s Disease
role against oligodendroglial alteration and neurodegener-
ation [57]. Ablation of toll-like receptor 4 (TLR-4) in a
tg mouse model of MSA with oligodendroglial αSo v e r e x -
pression augmented motor disability and enhanced loss of
nigrostriatal dopaminergic neurons, which were associated
with increased brain levels of αS linked to disturbed TLR-4-
mediated microglial phagocytosis of αS[ 57]. Taken together,
these results suggest that both astrocytes and microglia have
protective roles in αSt gm i c ei nt h eM S Am o d e l .
7. Conclusions andPerspectives
The results from genetically engineered mouse models of
PD and related α-synucleinopathies strongly suggest that
the mechanism of glial activation of chronic model α-
synucleinopathies in αS tg mice is distinct from that in
drug (e.g., MPTP)-induced acute parkinsonian models,
which are characterized by rapid and extensive activation of
microglia upon drug treatment, followed by mild activation
of astrocytes [11]. In αS tg mice, astrocytes may respond
to αS released from degenerating neurons to protect against
neurodegeneration (Figure 2). During the long time course
of neurodegeneration, these activated astrocytes may lose
their protective properties or might be aberrantly activated,
leading to stimulation of neuroinﬂammation. In contrast,
microglia are not readily activated unless they are stimulated
with an inﬂammagen such as LPS or through alterations of
other familial PD risk factors such as parkin, PINK1 and
LRRK2 (Figure 2). The ﬁnding that microglia are not easily
activated in αS tg mice raises the possibility that activation
of microglia might be a relatively late event during chronic
development of α-synucleinopathies. Thus, this may be
comparable to Lewy body formation and massive neuronal
cell death, both of which are histopathological hallmarks
of autopsy brains. In support of this notion, we found
thatmicrogliaareactivated(Figure 1(b))concomitantlywith
neuronal cell death in a bigenic mouse expressing both αS
and P123HβS, but not in single tg mouse expressing αSo r
P123HβS (Figures 1 and 2)[ 28]. It is also possible that,
similarly to astrocytes, microglia are protective during the
early stage of neurodegeneration. This possibility may be
supported by a crossing experiments with αSt gM S Am o d e l
mice and TLR-4 knockout mice [57].
It is unclear whether αS tg mice are appropriate for
analysisofthepossiblealterationofastrocytesandmicroglial
activation in the late stage of PD. However, αSt gm i c e
may provide a means to address fundamental aspects of
the early stage of α-synucleinopathies in the period in
which astrocytes and microglia have protective roles against
neurodegeneration. An understanding of the pathogenic
mechanism in the early stage of a disease is essential for
early diagnosis and implementation of a protective strategy.
αS tg mice models are invaluable for this purpose, including
evaluation of the early stage of neuroinﬂammation.
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